Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MC230808 Reduced Dose Hypofractionated Radiotherapy (3Gy x 3 Fractions) for Indolent Non-Hodgkin Lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial

NCT06386315 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06386315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06386315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MC230808 Reduced Dose Hypofractionated Radiotherapy (3Gy x 3 Fractions) for Indolent Non-Hodgkin Lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
May 15, 2024
Completion date
May 30, 2027
Enrollment
112 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

indolent b-cell non-hodgkin lymphoma, recurrent indolent b-cell non-hodgkin lymphoma, recurrent indolent non-hodgkin lymphoma, refractory indolent b-cell non-hodgkin lymphoma, refractory indolent non-hodgkin lymphoma